Study reveals cause, potential precision therapies for aggressive type of lymphoma
DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets. But this process can go awry in people with a mutation in a gene called SETD2, leading to a type of aggressive blood cancer, according to a new study.
Read Original Article: Study reveals cause, potential precision therapies for aggressive type of lymphoma »
